Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2022-12-12 Major Shareholding Noti…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the acquisition of shares by Quad Investment Management Corp. in LegoChem Biosciences. This type of filing is a mandatory disclosure of significant share ownership changes, which falls under the 'Major Shareholding Notification' category.
2022-12-12 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and provides the outcome of a specific agenda item (capital reserve deficit compensation) voted on during the meeting held on 2022-12-01. This falls under the category of official results from shareholder votes at a general meeting.
2022-12-01 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for LegoChem Biosciences. It outlines the meeting date, location, and specific agenda items (such as the resolution for capital reserve deficit compensation). It also includes detailed management information, such as board activity reports and business overviews, which are standard components of proxy materials provided to shareholders to inform their voting decisions. Since this document serves as the official solicitation and information package for an upcoming shareholder meeting, it is classified as a Proxy Solicitation & Information Statement.
2022-11-16 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for LegoChem Biosciences, Inc. for the 3rd quarter of the 17th fiscal year (ending September 30, 2022). It contains detailed financial information, company overview, capital changes, and management discussion, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (임시주주총회). It does not contain the full proxy materials or the meeting results themselves, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement and its brevity, it falls under the category of general regulatory filings.
2022-10-18 Korean
주주총회소집결의
AGM Information Classification · 95% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for Legochem Biosciences, detailing the date, location, and agenda items (specifically the resolution to cover deficits using capital reserves). This type of document, which provides information to shareholders regarding an upcoming meeting and the matters to be voted upon, is classified as a Proxy Solicitation & Information Statement.
2022-10-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.